ANI Pharmaceuticals Inc. Surpasses Analyst Target Price of $83.12
ByAinvest
Tuesday, Aug 12, 2025 10:24 am ET1min read
ANIP--
The recent price surge follows the company's strong second-quarter 2025 results. ANI Pharmaceuticals reported an adjusted earnings per share (EPS) of $1.80, surpassing the FactSet consensus estimate of $1.41. Revenue also exceeded expectations, reaching $211.4 million compared to the forecast of $187.34 million [1][2].
A significant contributor to the strong financial performance was Cortrophin Gel, which generated $81.6 million in revenue, marking a 66% year-over-year increase and a 54% sequential rise from Q1 2025. The company has raised its guidance for Cortrophin Gel to between $322 million and $329 million for 2025 [2].
Analysts have responded to these results with increased price targets. Truist Securities raised its price target to $77.00 from $65.00, maintaining a Hold rating, while H.C. Wainwright increased its target to $93.00 from $84.00, maintaining a Buy rating [1][2].
Investors should assess ANI Pharmaceuticals' valuation and decide whether the stock has become overvalued or if there is room for further growth. The company's strong performance and positive outlook from analysts suggest continued growth potential.
References:
[1] https://www.investing.com/news/analyst-ratings/ani-pharmaceuticals-stock-price-target-raised-to-77-from-65-at-truist-securities-93CH-4183314
[2] https://www.investing.com/news/analyst-ratings/ani-pharmaceuticals-stock-price-target-raised-to-93-from-84-at-hc-wainwright-93CH-4182592
FDS--
ANI Pharmaceuticals Inc (ANIP) shares have crossed above the average analyst 12-month target price of $83.12, trading at $84.88/share. The average analyst target is based on 8 different analyst targets, ranging from $65 to $94. Investors should assess the company and decide whether the valuation has gotten stretched or if there is room for further growth.
ANI Pharmaceuticals Inc (ANIP) shares have surged above the average analyst 12-month target price of $83.12, trading at $84.88 per share. The average target is based on eight different analyst estimates, ranging from $65 to $94 [1][2].The recent price surge follows the company's strong second-quarter 2025 results. ANI Pharmaceuticals reported an adjusted earnings per share (EPS) of $1.80, surpassing the FactSet consensus estimate of $1.41. Revenue also exceeded expectations, reaching $211.4 million compared to the forecast of $187.34 million [1][2].
A significant contributor to the strong financial performance was Cortrophin Gel, which generated $81.6 million in revenue, marking a 66% year-over-year increase and a 54% sequential rise from Q1 2025. The company has raised its guidance for Cortrophin Gel to between $322 million and $329 million for 2025 [2].
Analysts have responded to these results with increased price targets. Truist Securities raised its price target to $77.00 from $65.00, maintaining a Hold rating, while H.C. Wainwright increased its target to $93.00 from $84.00, maintaining a Buy rating [1][2].
Investors should assess ANI Pharmaceuticals' valuation and decide whether the stock has become overvalued or if there is room for further growth. The company's strong performance and positive outlook from analysts suggest continued growth potential.
References:
[1] https://www.investing.com/news/analyst-ratings/ani-pharmaceuticals-stock-price-target-raised-to-77-from-65-at-truist-securities-93CH-4183314
[2] https://www.investing.com/news/analyst-ratings/ani-pharmaceuticals-stock-price-target-raised-to-93-from-84-at-hc-wainwright-93CH-4182592
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet